bioAffinity Technologies jumped 47.95% on September 2, one day after announcing that it was advancing the potential use of CyPath Lung for post-treatment surveillance of lung-cancer patients. The move followed a 1-for-15 reverse split that became effective for trading on August 24, a combination that can produce dramatic percentage swings in a thinly traded stock. bioAffinity Technologies, Inc. (NASDAQ:BIAF) uses artificial intelligence with flow cytometry to analyze sputum samples for signs associated with lung cancer.
Photographee.eu/Shutterstock.com
The commercial thesis is compelling if adoption follows. Second-quarter CyPath Lung test volume increased 216% year over year. A published clinical study reported 92% sensitivity, 87% specificity, 88% accuracy, and a 99% negative predictive value among high-risk patients with pulmonary nodules smaller than 20 millimeters. Expanding into surveillance can increase the number of addressable tests because patients may need monitoring after treatment rather than only an initial diagnostic decision.
The financial base is extremely small. bioAffinity posted a $3.4 million Q2 net loss, compared with $4.1 million a year earlier, and had $2.4 million of cash at quarter-end, down from $6.4 million at December 31. A June offering produced $3.2 million of gross proceeds and about $2.6 million of estimated net proceeds. The company then closed another $4 million gross private placement on August 14. That capital supports commercialization, but the pre-funded and other warrants created additional dilution risk. The reverse split was intended to help restore Nasdaq listing compliance without changing the underlying economics
Hedge-fund participation remains minimal. Insider Monkey tracked two funds holding bioAffinity Technologies, Inc. in both Q2 and Q1. With so few funds involved, small transactions can distort percentage comparisons.
Short positioning requires a split adjustment. The August 14 settlement showed 195,685 pre-split shares short, down from 327,035, with 1.0 days to cover. The August 24 one-for-15 reverse split makes that roughly 13,046 post-split shares. Float percentages published across data services are not comparable around the event, so the adjusted share count is the defensible reference.
For the rally to become durable, bioAffinity needs more than clinical percentages and a new use case. It must convert physician interest into reimbursed test volume, produce credible revenue growth, and finance that expansion without repeatedly resetting the share count. The technology offers real optionality, but the balance sheet keeps the investment firmly speculative. Investors should verify payer coverage, average reimbursement, laboratory capacity, and quarterly cash burn. A rising test count will be most valuable if revenue per test is stable and collection times remain manageable. Otherwise, faster adoption could require additional capital before the business reaches sustainable scale.
READ NEXT: NVIDIA (NVDA): What Foxconn and Super Micro Are Telling Us about the AI Boom and Pony AI Is Scaling Robotaxis Fast—Can the Stock Reach BofA’s $17 Target?
Follow Insider Monkey on Google News.
